CN117295496A - 用于治疗胰腺癌的自分泌运动因子(atx)抑制剂 - Google Patents

用于治疗胰腺癌的自分泌运动因子(atx)抑制剂 Download PDF

Info

Publication number
CN117295496A
CN117295496A CN202280032188.0A CN202280032188A CN117295496A CN 117295496 A CN117295496 A CN 117295496A CN 202280032188 A CN202280032188 A CN 202280032188A CN 117295496 A CN117295496 A CN 117295496A
Authority
CN
China
Prior art keywords
compound
pancreatic cancer
salt
use according
gemcitabine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280032188.0A
Other languages
English (en)
Chinese (zh)
Inventor
Z·约翰逊
M·德肯
M·拉恩
D·梅利西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionketura LLC
Original Assignee
Ionktura Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionktura Co ltd filed Critical Ionktura Co ltd
Publication of CN117295496A publication Critical patent/CN117295496A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280032188.0A 2021-06-09 2022-06-08 用于治疗胰腺癌的自分泌运动因子(atx)抑制剂 Pending CN117295496A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2108245.8 2021-06-09
GBGB2108245.8A GB202108245D0 (en) 2021-06-09 2021-06-09 Methods of treatment
PCT/EP2022/065562 WO2022258693A1 (en) 2021-06-09 2022-06-08 Autotaxin (atx) inhibitor for the treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
CN117295496A true CN117295496A (zh) 2023-12-26

Family

ID=76838834

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280032188.0A Pending CN117295496A (zh) 2021-06-09 2022-06-08 用于治疗胰腺癌的自分泌运动因子(atx)抑制剂

Country Status (9)

Country Link
US (1) US20250057820A1 (https=)
EP (1) EP4351563A1 (https=)
JP (1) JP2024522135A (https=)
CN (1) CN117295496A (https=)
AU (1) AU2022290378A1 (https=)
CA (1) CA3218103A1 (https=)
GB (1) GB202108245D0 (https=)
MX (1) MX2023014637A (https=)
WO (1) WO2022258693A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201502020D0 (en) * 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
JP2024511836A (ja) * 2021-03-29 2024-03-15 アイオンクチュラ・ソシエテ・アノニム 膵臓癌の治療のためのｐｉ３ｋ－デルタ阻害剤

Also Published As

Publication number Publication date
CA3218103A1 (en) 2022-12-15
GB202108245D0 (en) 2021-07-21
US20250057820A1 (en) 2025-02-20
JP2024522135A (ja) 2024-06-11
EP4351563A1 (en) 2024-04-17
AU2022290378A1 (en) 2024-01-04
MX2023014637A (es) 2024-01-31
WO2022258693A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
KR102713072B1 (ko) 두경부암 치료를 위한 egfr 저해제
USRE46284E1 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
EP2785349B1 (en) Combination treatment of cancer
CN101360495B (zh) 对癌症病人给药mTOR抑制剂
US20160193211A1 (en) Combinations of a btk inhibitor and fluorouracil for treating cancers
Hedayat et al. Selumetinib: a selective MEK1 inhibitor for solid tumor treatment
US20160256529A1 (en) Combination therapy
CN103533940A (zh) 治疗晚期实体瘤的方法
JP2009536956A (ja) 抗癌治療法
TW201141473A (en) Combination therapy for small cell lung cancer
CN117295496A (zh) 用于治疗胰腺癌的自分泌运动因子(atx)抑制剂
US11648235B1 (en) Treatment of glioblastoma
WO2021175432A1 (en) Method for administration of an anti cancer agent
EP1757283B1 (en) Antitumor effect fortifier, antitumor agent and method of therapy for cancer
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
RU2519199C2 (ru) Противоопухолевый агент, набор и способ лечения рака
JP2005255643A (ja) 抗腫瘍効果増強方法および抗腫瘍効果増強剤
JP7450037B2 (ja) 脳転移を有する末期非小細胞肺がん患者を治療するための組み合わせ医薬品
CN102939086B (zh) 胃癌的治疗方法
EP4719405A1 (en) Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
HK40103578A (en) Egfr inhibitor for the treatment of head and neck cancer
HK40103578B (en) Egfr inhibitor for the treatment of head and neck cancer
Kikuchi et al. 3510 POSTER Serum vascular endothelial growth factor (VEGF), VEGF receptor-1 and-2 among gastric cancer patients and healthy subjects
Kim et al. 3509 POSTER Growth inhibitory effects and mechanisms of lapatinib, a dual inhibitor of ErbB1 and ErbB2 tyrosine kinase, in gastric cell lines
JP2004514683A (ja) レバミゾール及び５−フルオロウラシルの同時投与法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240327

Address after: Netherlands

Applicant after: Ionketura LLC

Country or region after: Netherlands

Address before: Geneva, Switzerland

Applicant before: Ionktura Co.,Ltd.

Country or region before: Switzerland

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination